Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

AVNS earnings analysis

Filed May 5, 2026 · Our reading of the company's report

The latest report

Avanos Medical reported Q1 2026 revenue of $182.2 million, exceeding expectations and up 8.8% year-over-year, driven by a notable 22.7% growth in its Specialty Nutrition Systems segment. Diluted EPS of $0.22 also…

Read full summary

Avanos Medical reported Q1 2026 revenue of $182.2 million, exceeding expectations and up 8.8% year-over-year, driven by a notable 22.7% growth in its Specialty Nutrition Systems segment. Diluted EPS of $0.22 also surpassed estimates, reflecting management's focus on operational restructuring amid ongoing tariff impacts.

Read the original on SEC.gov

Where revenue came from

The business segments reported by the company.

Specialty Nutrition Systems 68.1% Pain Management and Recovery 30.9% Corporate and Other 1.0%

Shares of the segments disclosed in this filing, largest first.

Reported figures

Earnings per share
$0.22
Operating margin
4.9%

What stood out

  • Robust Revenue Growth

    Total revenue reached $182.2 million, up 8.8% from $167.5 million in Q1 2025.

  • Strong EPS Performance

    Diluted EPS was reported at $0.22, exceeding the estimate of $0.16 and higher than the prior period's $0.14.

  • Specialty Nutrition Systems Surge

    Specialty Nutrition Systems segment grew by 22.7%, contributing $124.0 million to total revenue.

  • Cost Reduction Initiatives

    Restructuring efforts yield annualized savings expected between $15.0 million and $20.0 million.

  • Reduced Interest Expense

    Interest expense decreased to $1.5 million from $2.1 million year-over-year, benefiting from lower debt levels.

  • Operating Cash Flow Improvement

    Operating cash flow was negative but improved with cash usage down to $12.3 million in Q1 2026 from $25.7 million in Q1 2025.

What to watch

  • Negative Operating Margin

    Operating margin dropped to 4.9% in Q1 2026 from 6.0% in Q1 2025, indicating ongoing margin pressure.

  • Cash Decrease

    Cash and cash equivalents declined by $24.2 million to $65.6 million, reflecting higher operational costs.

  • Impact of Tariffs

    Increased tariffs contributed to rising costs in the Specialty Nutrition Systems segment, creating margin challenges.

Management's outlook

Management expects to utilize operating cash flow for working capital needs; specific revenue guidance not provided.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.